KLIFO Appoints René Pedersen as New CEO

Glostrup, Denmark – 22 May 2025 – KLIFO announced today the appointment of René Pedersen as CEO, effective immediately. René has served as KLIFO’s CFO for the past two years and more recently as Acting CEO. Hence he now formally assumes the role of CEO as the company advances into its next growth phase.

The appointment follows a comprehensive search process led by the Board of Directors, supported by international advisors, and included a detailed evaluation of both internal and external candidates.

Niels Peder Nielsen, Chairman of the Board, commented: “The Board is very pleased to appoint René Pedersen as KLIFO’s new CEO. Through a rigorous selection process, René stood out as the candidate with the right strategic mindset, leadership experience, and deep understanding of KLIFO’s business and values. We are confident that he is the right person to lead the company into its next chapter.”

René brings over 20 years of industry experience within life science, having held leadership roles at Novo Nordisk, NNE, and TFS. His experience spans the entire value chain—from strategy and operations to production, sales and finance. During his time at KLIFO, René has played a key role in the company’s strategic transformation and financial strengthening.

René Pedersen stated: “I am honoured to lead KLIFO at this exciting time in our journey. With strong momentum, talented teams, and a clear vision, we are well-positioned to deliver sustainable, profitable growth. I look forward to continuing to build on KLIFO’s strong foundation and further expanding our ability to support clients across the entire drug development”

As CEO, René will focus on accelerating KLIFOs growth strategy within premium Drug Development Consultancy and Clinical Trial Supply, where KLIFO are taking significant steps forward. KLIFO is about to launch a new state-of-the-art Clinical Trial Supply facility in the Copenhagen area quadrupling our capacity and we are continuing to scale our premium advisory business across all advisory areas, Drug Development, Regulatory Affairs, CMC, and Clinical Development. In parallel, KLIFO is actively exploring M&A opportunities and strategic partnerships, aimed at expanding capabilities and accelerating innovation for clients globally.